Common Contracts
7 similar Joint Filing Agreement contracts by Biotechnology Value Fund L P
Joint Filing AgreementJoint Filing Agreement • November 9th, 2017 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Schedule 13G dated November 9, 2017 with respect to the shares of Common Stock of Spero Therapeutics, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • April 10th, 2017 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Schedule 13G dated April 10, 2017 with respect to the shares of Common Stock of BioLineRx Ltd., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • December 1st, 2016 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Schedule 13G dated December 1, 2016 with respect to the shares of Common Stock of Fate Therapeutics, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • November 18th, 2016 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Schedule 13G dated November 18, 2016 with respect to the shares of Common Stock of XOMA Corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • November 14th, 2016 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Schedule 13G dated November 14, 2016 with respect to the shares of Common Stock of Immune Design Corp., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • July 19th, 2016 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Schedule 13G dated July 18, 2016 with respect to the shares of Common Stock of Orexigen Therapeutics, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • June 17th, 2016 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Schedule 13G dated June 17, 2016 with respect to the shares of Common Stock of Pieris Pharmaceuticals, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
